Synthetic promoters enhance gene therapy precision
Discover how Chromatin Bioscience’s synthetic promoters are transforming gene therapy by enhancing precision, boosting safety and improving manufacturing efficiency.
List view / Grid view
Discover how Chromatin Bioscience’s synthetic promoters are transforming gene therapy by enhancing precision, boosting safety and improving manufacturing efficiency.
rBIO is transforming the biosimilar insulin market with a novel biomanufacturing platform designed to reduce production costs while maintaining high-quality standards. CEO Cameron Owen shares how their approach is shaping drug discovery and improving patient access to life-saving treatments.
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a…
A synthetic antibody selectively activates the Wnt signalling pathway and directs stem cells to differentiate into neurons.
Researchers have created a novel molecule, which has an improved ability to bind to bacterial ribosomes, with a completely synthetic system.
Using a nanofluidic aptamer nanoarray to measure biomolecules including proteins, Japanese researchers are attempting to bridge the gap for precision medicine
Drug Target Review connects with Dr Stefan Braam, co-founder and CTO of Cellistic, and Andy Holt, CCO of Cellistic, for a rundown on today’s landscape for allogeneic cell therapies.
Chinese scientists have developed a synthetic tissue that repairs penile injuries and restores normal erectile function in pigs.
German researchers have designed peptides that bind to amyloidogenic proteins linked to Alzheimer’s and type 2 diabetes, to effectively suppress both cytotoxic amyloid aggregation and amyloid cross-accelerating interactions.
Researchers have streamlined the traditionally slow process of enzyme engineering. This work might help researchers tailor the suitability of enzymes for custom purposes.
MIT researchers have developed a technique that could help the production of monoclonal antibodies and other useful proteins.